Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
328 total articles
Applied Materials ($327.65) is an attractive buy ahead of its Q1 2026 report. The company sits squarely in the AI-driven semiconductor capital expenditure cycle, shows healthy profitability (ROE ~34%), and generates meaningful free cash flow ($5.698B). Valuation is not cheap, but the combination of improving order signals across the supply chain an…
Power Solutions International looks like a pragmatic way to play data center infrastructure without paying frothy multiples. The company is profitable, generating free cash flow, and is benefiting from demand for power systems in AI/data-center builds. Recent headlines and a meaningful retracement create a deep-value entry point at roughly a mid-te…
Paysafe trades near multi-month lows after a client-related write-down and ongoing securities probes. The business still owns recognizable digital-wallet assets (Skrill, NETELLER) and is cheap on price-to-book. This trade idea aims to capture a mid-term rebound on improving fundamentals and recent commercial partnerships while respecting headline r…
EMCOR (EME) has given back some of the dramatic gains that came with the AI/data‑center narrative, but the core business metrics remain strong: $1.15B in free cash flow, ROE near 34%, and limited apparent leverage. The near-term headline volatility creates an opportunity to buy a base above the 10/20/50-day moving averages with a clear risk-managem…
SLC Agrícola's ADRs trade near $3 with technicals showing recent strength and a clear valuation case for upside. However, low liquidity, sporadic heavy shorting and near-term seasonal pressures make entry timing sensitive. This trade idea outlines a measured long with explicit entry, stop and target tailored to a mid-term horizon.
Nvidia's runaway data-center demand and massive free cash flow make it the single most important demand driver in the AI infrastructure cycle. Given hyperscalers' aggressive capex plans, Nvidia is positioned to keep pricing power and revenue momentum. Trade idea: go long NVDA for a mid-term run as AI spending and technical momentum push shares high…
AppFolio's recent pullback has pushed the stock into oversold territory while fundamentals - 21% revenue growth in the last reported quarter and healthy free cash flow - remain intact. Multiples compressed faster than growth decelerated; that creates a tactical buying window for investors willing to hold for a mid-term re-rating driven by product m…
Exxon Mobil combines scale, steady cash generation and aggressive capital returns. With Q4 2025 production records, $12.7B operating cash flow and a $20B buyback program for 2026, the stock merits a long trade. Entry at current levels, a tight stop to protect downside and a mid‑to‑long term target reflect measured upside against clear macro and com…
Kaspi is transitioning from a P2P payments story to a merchants-and-mcommerce play inside its Super App. With a $15.5B market cap, a P/E of 7.0, and a 5.7% dividend yield, the stock looks attractively priced for a mid‑term swing as merchant GMV and take rates rise. This trade plan identifies an entry at $79.21, conservative stop at $72.00, and a ta…
Moderna's pivot away from COVID-only revenues into oncology and a planned flu launch gives it a clearer multi-year path than many vaccine peers. At $44.64 today and a market cap near $17.4B, the risk/reward favors a measured long with defined stops while Novavax remains a qualitative comparator given limited public data in this note.
Hims & Hers (HIMS) is repositioning from a direct-to-consumer retailer into a multi-service telehealth platform. At about $28.72 today and a market cap near $6.5B, the stock trades at a premium multiple but shows improving unit economics, positive free cash flow, and a large, addressable market in weight management, mental health and primary care. …
Nvidia remains the dominant supplier of AI infrastructure with accelerating data-center demand, rare margins and cash generation, and bullish technicals. At roughly $192, the shares offer a compelling risk/reward for a long trade with a $260 target over a 180 trading-day horizon. Valuation is rich on paper, but growth and cash flow justify a discip…
Alphabet ($GOOGL) looks positioned to outperform into and through its upcoming Q4 report. The stock trades near $338 with a ~$4.08 trillion market cap, robust free cash flow of $73.6B and a clean balance sheet. Recent headlines around AI, AR hardware, and cloud traction make this a sensible upgrade to a long trade into earnings, paired with a stric…
Netflix is down sharply from its 2025 highs after the proposed acquisition of Warner Bros. Discovery and a broader tech sell-off. The core streaming business remains profitable with strong cash generation and healthy margins; the market has largely priced in deal execution and leverage risk. For disciplined traders, this creates a defined-risk long…
HubSpot (HUBS) has been knocked down after guidance concerns and sector rotation, but the company still generates meaningful free cash flow, carries no debt, and sits at oversold technicals. This trade targets a mid-term rebound while protecting capital with a tight stop under recent lows.
Molina Healthcare ($MOH) sold off after CMS proposed a 0.09% Medicare Advantage rate increase for 2027 on 01/27/2026. The pullback creates a mid-term swing entry into a company with a $9.5B market cap, P/E near 11, and deep Medicaid exposure (roughly 75% of revenue). We recommend buying the dip with a clear entry, stop and target and a 45-trading-d…
Palladyne AI pairs hardware robotics with autonomy software and a recent cybersecurity partnership. The market is pricing the company like a growth software story while revenue proof is still emerging. We think a mid-term long trade captures re-rating potential from new contract wins and recurring software sales, while respect for headline valuatio…
Microsoft has been weak on AI anxiety headlines, but beneath the headlines the company still posts strong cloud growth, a massive $625B commercial backlog, $77.4B in free cash flow and a fortress balance sheet. The market is trading off near-term execution fears; that creates a tactical buy opportunity for a swing trade with defined risk.
EVgo is showing early signs of an earnings-quality turnaround: record charging revenue, faster station deployment via prefabricated skids and rapid Autocharge+ adoption. With an enterprise value of ~$453M, improving unit economics and a healthy cash buffer, EVgo looks positioned for a rating upgrade. This trade plan targets a move to $4.50 over the…
Bitdeer is trading like a pure bitcoin miner after a bruising R&D miss and class‑action headlines. The company still controls datacenter capacity, has visible short interest and technical support, and — critically — is pursuing a full‑stack compute play (SEAL04 ASIC + systems) that the market has largely discounted. I’m recommending a mid‑term swin…
OCANF shows bullish technicals: price trading above the 10/20/50-day moving averages, an RSI under 70, and a bullish MACD. Short interest has collapsed from multi-million share levels to ~318k shares with days-to-cover at 7.6, setting up a measured long where a short squeeze can amplify gains. Entry $36.77, stop $32.50, target $45.00 for a mid-term…
TXO Partners (TXO) trades near $12 with a 16%+ distribution yield, a low debt-to-equity ratio of 0.37 and an EV/EBITDA of ~10.6. This trade idea targets a mid-term re-rate into the low-teens/teens driven by yield-hungry buyers and improving operational headlines. Entry $11.98, stop $10.30, target $15.00, horizon: mid term (45 trading days).
InfuSystem (INFU) is a cash-generative provider of home infusion and device services trading at about $8.00. Modest growth, improving margins and a sensible balance sheet make it a reasonable mid-term long trade if regulatory clarity or reimbursement tailwinds materialize. Entry $7.95, stop $7.20, target $10.50 over ~45 trading days.
Viemed Healthcare is trading at reasonable multiples versus its cash-flow profile and operating momentum. The combination of a modest enterprise value, positive free cash flow and an improving patient and revenue backdrop supports a mid-term long trade with a well-defined entry, stop and target.
Cadence (CDNS) remains a clear beneficiary of the AI-driven demand for simulation, verification and semiconductor IP, yet today’s pullback after a sharp run leaves valuation stretched. We lay out a mid-term swing trade that leans long into the company’s secular momentum while protecting capital with a tight stop.
